Oxford BioMedica (OXBDF) Lifted to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Oxford BioMedica (OTCMKTS:OXBDF) from a sell rating to a hold rating in a research report released on Thursday.

According to Zacks, “Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. “

Shares of OXBDF opened at $8.83 on Thursday. Oxford BioMedica has a 52 week low of $5.00 and a 52 week high of $22.50.

About Oxford BioMedica

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.

Read More: Cash Flow

Get a free copy of the Zacks research report on Oxford BioMedica (OXBDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit